JP2014510122A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510122A5
JP2014510122A5 JP2014503105A JP2014503105A JP2014510122A5 JP 2014510122 A5 JP2014510122 A5 JP 2014510122A5 JP 2014503105 A JP2014503105 A JP 2014503105A JP 2014503105 A JP2014503105 A JP 2014503105A JP 2014510122 A5 JP2014510122 A5 JP 2014510122A5
Authority
JP
Japan
Prior art keywords
phenyl
pyrrolo
dihydro
methylmorpholino
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014503105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510122A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055953 external-priority patent/WO2012136622A1/en
Publication of JP2014510122A publication Critical patent/JP2014510122A/ja
Publication of JP2014510122A5 publication Critical patent/JP2014510122A5/ja
Pending legal-status Critical Current

Links

JP2014503105A 2011-04-04 2012-04-02 ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体 Pending JP2014510122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160983 2011-04-04
EP11160983.0 2011-04-04
PCT/EP2012/055953 WO2012136622A1 (en) 2011-04-04 2012-04-02 Dihydropyrrolo pyrimidine derivatives as mtor inhibitors

Publications (2)

Publication Number Publication Date
JP2014510122A JP2014510122A (ja) 2014-04-24
JP2014510122A5 true JP2014510122A5 (enExample) 2015-05-21

Family

ID=44246546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503105A Pending JP2014510122A (ja) 2011-04-04 2012-04-02 ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体

Country Status (4)

Country Link
US (1) US20140163023A1 (enExample)
EP (1) EP2694511A1 (enExample)
JP (1) JP2014510122A (enExample)
WO (1) WO2012136622A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
CA2849189A1 (en) 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
JP5995977B2 (ja) 2011-10-07 2016-09-21 セルゾーム リミテッド Ｍｔｏｒ阻害剤としてのモルホリノ置換二環式ピリミジン尿素またはカルバメート誘導体
WO2015055071A1 (zh) 2013-10-16 2015-04-23 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
WO2018001944A1 (en) 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN111606926B (zh) * 2020-05-13 2021-10-15 大连理工大学 一种苯并咪唑[1,3]氮硫杂卓类化合物的制备方法
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280930C (en) 1997-02-12 2010-04-06 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
US7135298B2 (en) 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
ATE414281T1 (de) 2006-08-03 2008-11-15 Cellzome Ag Verfahren zur identifizierung von molekülen die mit pi3k interagieren und verfahren zur reinigung von pi3k
JP5534811B2 (ja) 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
EP2178866A2 (en) 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
BRPI0814818A2 (pt) 2007-07-09 2019-09-10 Astrazeneca Ab composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
WO2009045174A1 (en) * 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
CN101224207A (zh) 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
WO2009098021A1 (en) 2008-02-04 2009-08-13 Cellzome Ag Selectivity profiling of pi3k interacting molecules against multiple targets
JP2011527342A (ja) 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
WO2010053825A1 (en) * 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
WO2010056320A2 (en) 2008-11-11 2010-05-20 Tyrogenex, Inc. Pi3k/mtor kinase inhibitors
EP2406258B1 (en) 2009-03-13 2014-12-03 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120987A1 (en) 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
ES2439793T3 (es) * 2009-04-17 2014-01-24 Wyeth Llc Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2010120991A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
CA2768851A1 (en) 2009-07-23 2011-01-27 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors

Similar Documents

Publication Publication Date Title
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
RU2019115115A (ru) Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7
JP6192839B2 (ja) ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド
JP5657556B2 (ja) α７選択的リガンドを用いる治療
JP2019535664A5 (enExample)
JP2014530197A5 (enExample)
JP2023525035A5 (enExample)
JP2016028073A (ja) キナーゼ調節のための化合物および方法、ならびにそれらの適応症
RU2014115476A (ru) Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
JP2020510010A5 (enExample)
JP2014531449A5 (enExample)
RU2015121374A (ru) Ингибиторы alk-киназы
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
RU2010116759A (ru) Пиримидиновые производные, используемые в качестве ингибиторов протеинкиназы
JP2012501312A5 (enExample)
JP2014528436A5 (enExample)
CA2473026A1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
RU2014128307A (ru) Пиррольное производное шестичленного гетероарильного кольца, способ его получения и его медицинское применение
EA023824B1 (ru) ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
RU2010117156A (ru) Гетероциклические соединения в качестве антагонистов crth2 рецептора
ZA202001390B (en) Crystalline forms
RU2014109747A (ru) Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
RU2010148534A (ru) Производные имидазолидинона в качестве ингибиторов в 11b-hsd1
JP2007528394A5 (enExample)
RU2012128551A (ru) Производные этинила